S. Montgomery

发表

Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials

A. Serretti, C. Fabbri, F. Corponi, 2017, International clinical psychopharmacology.

High plasma nortriptyline levels in the treatment of depression. I

R. Braithwaite, S. Dawling, S. Montgomery, 1978, Clinical pharmacology and therapeutics.

The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs.

D. Rujescu, A. Serretti, L. Bartova, 2022, Journal of Affective Disorders.

The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries

D. Rujescu, A. Serretti, L. Bartova, 2022, European Archives of Psychiatry and Clinical Neuroscience.

Drug repositioning for treatment-resistant depression: insights from a pharmacogenomic study

Albani, D. Rujescu, A. Serretti, 2020 .

Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients

A. Serretti, S. Kasper, J. Mendlewicz, 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting

D. Rujescu, A. Serretti, S. Kasper, 2022, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression.

A. Serretti, L. Bartova, S. Kasper, 2021, Journal of psychiatric research.

Polygenic risk scores for psychiatric, inflammatory, and cardio-metabolic traits and diseases highlight possible genetic overlaps with suicide attempt and treatment-emergent suicidal ideation European College of Neuropsychopharmacology (ECNP) Network on Suicide Research and Prevention,

D. Rujescu, D. Souery, J. Zohar, 2021 .

Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns.

D. Rujescu, A. Serretti, S. Kasper, 2022, Journal of affective disorders.

P.021 Social dysfunction in mood disorders and schizophrenia: clinical correlates in four independent samples

D. Rujescu, A. Serretti, S. Kasper, 2019, European Neuropsychopharmacology.

Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression

A. Serretti, S. Kasper, J. Mendlewicz, 2012, Neuroscience Letters.

New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder

J. Endicott, G. Muscettola, K. Demyttenaere, 2002, Archives of Women's Mental Health.

Treatment resistant depression: methodological overview and operational criteria

J. Amsterdam, C. Montigny, Y. Lecrubier, 1999, European Neuropsychopharmacology.

Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples

D. Rujescu, B. Penninx, A. Serretti, 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

The role of noradrenaline and selective noradrenaline reuptake inhibition in depression

E. Paykel, S. Kasper, J. Mendlewicz, 2002, European Neuropsychopharmacology.

The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder — A European Multicenter Study

A. Serretti, S. Kasper, D. Souery, 2012, European Neuropsychopharmacology.

European Group for the Study of Resistant Depression (GSRD) — Where have we gone so far: Review of clinical and genetic findings

A. Serretti, S. Kasper, J. Mendlewicz, 2012, European Neuropsychopharmacology.

Genetic variants associated with psychotic symptoms across psychiatric disorders

A. Serretti, L. Mandelli, S. Kasper, 2020, Neuroscience Letters.

Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation

D. Rujescu, A. Serretti, D. Wasserman, 2022, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Polygenic risk scores for psychiatric, inflammatory, and cardio-metabolic traits and diseases highlight possible genetic overlaps with suicide attempt and treatment-emergent suicidal ideation

D. Rujescu, A. Serretti, D. Wasserman, 2021, medRxiv.

Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study

D. Rujescu, A. Serretti, S. Kasper, 2022, European Neuropsychopharmacology.

Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study

A. Serretti, L. Bartova, S. Kasper, 2019, European Neuropsychopharmacology.

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder

D. Rujescu, A. Serretti, L. Bartova, 2021, The international journal of neuropsychopharmacology.

Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD)

A. Serretti, L. Bartova, S. Kasper, 2018, European Neuropsychopharmacology.

Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance

A. Serretti, S. Kasper, J. Mendlewicz, 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study

A. Serretti, L. Bartova, S. Kasper, 2017, European Neuropsychopharmacology.

Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression

D. Rujescu, C. Lewis, A. Serretti, 2020, medRxiv.

Challenging sequential approach to treatment resistant depression: Cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR⁎D) trial

A. Serretti, P. Olgiati, E. Bajo, 2013, European Neuropsychopharmacology.

Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone

I. Bitter, A. Serretti, S. Kasper, 2019, European Neuropsychopharmacology.

Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study

D. Rujescu, C. Lewis, A. Serretti, 2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

P.335 Drug repositioning for treatment-resistant depression by comparing genetic predictors with known drug targets

D. Rujescu, A. Serretti, S. Kasper, 2020, European Neuropsychopharmacology.

High occupational level is associated with poor response to the treatment of depression: A replication study

A. Serretti, L. Mandelli, S. Kasper, 2019, European Neuropsychopharmacology.

Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study

A. Serretti, L. Bartova, U. Rabl, 2016, European Neuropsychopharmacology.

Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression

A. Serretti, L. Bartova, S. Kasper, 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder

A. Serretti, D. Souery, J. Zohar, 2013, European Neuropsychopharmacology.

Mineralocorticoid receptor-related markers and outcome of major depression: focus on blood pressure and electrolytes

H. Murck, M. Ploch, S. Montgomery, 2018, International clinical psychopharmacology.

A. Serretti, L. Mandelli, L. Bartova, 2021, Depression and anxiety.

A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response

D. Rujescu, A. Serretti, S. Kasper, 2021, European Neuropsychopharmacology.

Pharmacological therapies in post stroke recovery: recommendations for future clinical trials

F. Chollet, S. Cramer, C. Weiller, 2014, Journal of Neurology.

Current issues in bipolar disorder: A critical review

Y. Lecrubier, S. Kasper, J. Mendlewicz, 2007, European Neuropsychopharmacology.

Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study

A. Serretti, L. Bartova, S. Kasper, 2020, European Neuropsychopharmacology.

Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study.

A. Serretti, L. Bartova, S. Kasper, 2021, Journal of affective disorders.

Age as a moderating factor of treatment resistance in depression

D. Rujescu, A. Serretti, L. Bartova, 2023, European Psychiatry.

Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder.

D. Rujescu, A. Serretti, L. Bartova, 2023, Journal of affective disorders.

Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database.

A. Serretti, L. Bartova, S. Kasper, 2023, Journal of affective disorders.

High occupational level is associated with poor response to treatment of depression

A. Serretti, L. Mandelli, S. Kasper, 2016, European Neuropsychopharmacology.

Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder

D. Rujescu, A. Serretti, L. Bartova, 2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Melancholic features in major depression – a European multicenter study

A. Serretti, L. Bartova, S. Kasper, 2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study

A. Serretti, L. Bartova, S. Kasper, 2018, European Neuropsychopharmacology.

Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts

D. Rujescu, M. Kas, A. Serretti, 2021, International clinical psychopharmacology.

P.179 Polygenic risk scores for multiple psychiatric, inflammatory and cardio-metabolic traits highlight possible genetic overlap with suicide attempt

D. Rujescu, A. Serretti, D. Wasserman, 2020, European Neuropsychopharmacology.

Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with generalized anxiety disorder and insomnia

A. Krystal, T. Roth, W. McCall, 2007, European psychiatry.

5‐HT Reuptake Inhibitors, Tricyclic Antidepressants and Suicidal Behaviour

D. Baldwin, S. Montgomery, D. Montgomery, 1991, International clinical psychopharmacology.

Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression

D. Rujescu, K. Domschke, D. Souery, 2023, medRxiv.

P.171 Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder

D. Rujescu, A. Serretti, S. Kasper, 2020, European Neuropsychopharmacology.

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder

S. Montgomery, C. François, Jose-Luis Fernandez, 2012, PharmacoEconomics.

Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples

D. Souery, P. Ferentinos, S. Porcelli, 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.